Can existing flu shots help protect against bird flu?

Research highlighted on May 8, 2026, suggests that seasonal influenza vaccines currently in routine global use may significantly lower the risk of death from H5N1 bird flu infections. This finding comes as avian influenza continues to spread globally, moving from birds into mammals and, in rare instances, into humans.

The research, led by National Taiwan University in collaboration with University of South Florida Health, addresses a critical challenge in pandemic preparedness. Scientists are concerned that vaccines specifically designed to protect people against H5N1 may not be developed and distributed in time if a human pandemic emerges.

The Role of Neuraminidase N1

The findings were published in the journal Emerging Microbes & Infections. To reach these conclusions, the research team conducted a systematic review and analysis of ferret studies, which are considered the gold standard animal model for human influenza.

Over nearly two decades, the team analyzed experimental data from 35 controlled studies involving almost 1,800 ferrets. The analysis revealed that seasonal flu vaccines containing a specific component known as neuraminidase N1 reduced H5N1-related mortality by approximately 73% in vaccinated animals compared with unvaccinated animals.

This level of protection was found to be comparable to some H5N1-specific vaccines that failed to generate strong immune responses and was only modestly lower than those that did. In contrast, seasonal vaccines that lacked the N1 component showed little to no protective effect, indicating that specific elements of existing vaccines may play an outsized role in defending against emerging threats.

This work suggests that we may be underestimating the broader protective value of seasonal influenza vaccines. While they are not designed to target H5N1, certain components appear to activate immune responses that can reduce the severity of infection. In a real-world setting, that kind of partial protection could translate into lives saved while more specific vaccines are being developed and distributed.

Chi-Tai Fang, professor of infectious diseases epidemiology at National Taiwan University and National Taiwan University Hospital

Immune Mechanisms and Detection

The study also uncovered an unexpected detail regarding how this protection works. The seasonal vaccines did not produce detectable antibodies against H5N1 when analyzed using standard tests.

Instead, the researchers found that the protection likely stems from more complex immune mechanisms, specifically cross-reactive cellular responses. Because these responses are not captured by traditional measures of immunity, protection may exist even when it is not detectable through standard laboratory markers.

In a pandemic scenario, timing is everything. We often face a critical gap between the emergence of a new virus and the availability of a targeted vaccine. Our findings suggest that seasonal flu vaccination, something already widely available, could help reduce severe outcomes during that window. That is a meaningful advantage when every week matters.

Sten Vermund, dean of the USF Health College of Public Health and chief medical officer of the Global Virus Network

Implications for Public Health

These findings arrive as H5N1 continues to spread among mammals while global supplies of targeted vaccines remain limited. This gap leaves health systems vulnerable during the early stages of a potential outbreak.

While the researchers emphasize that seasonal flu vaccines are not a substitute for targeted vaccines, they suggest that extensive adoption of these available shots could buy critical time. By reducing deaths and easing the strain on health systems, routine vaccination may slow the impact of a rapidly spreading virus.

The research team cautioned that these findings are based on animal models and must be validated in humans. However, the study provides a new framework for understanding how existing immunity built through routine vaccination might shape the human response to emerging infectious diseases.